Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SHA:600332)
21.35
-0.20 (-0.93%)
May 28, 2026, 3:00 PM CST
Guangzhou Baiyunshan Pharmaceutical Holdings Company Employees
Guangzhou Baiyunshan Pharmaceutical Holdings Company had 27,057 employees as of December 31, 2025. The number of employees decreased by 991 or -3.53% compared to the previous year.
Employees
27,057
Change
-991
Growth
-3.53%
Revenue / Employee
2.90M CNY
Profits / Employee
108.86K CNY
Market Cap
32.92B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 27,057 | - | - |
| Jun 30, 2025 | 27,425 | - | - |
| Dec 31, 2023 | 28,048 | 3,799 | 15.67% |
| Dec 31, 2022 | 24,249 | -1,188 | -4.67% |
| Dec 31, 2021 | 25,437 | 269 | 1.07% |
| Dec 31, 2020 | 25,168 | -685 | -2.65% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Shanghai Pharmaceuticals Holding | 49,608 |
| China National Accord Medicines Corporation | 39,449 |
| Jointown Pharmaceutical Group | 29,862 |
| C.Q. Pharmaceutical Holding | 12,237 |
| China Meheco Group | 7,949 |
| Guangxi LiuYao Group | 5,513 |
| Liaoning Cheng Da | 3,317 |
| Qingdao Baheal Medical INC. | 3,064 |
Guangzhou Baiyunshan Pharmaceutical Holdings Company News
- 4 weeks ago - Guangzhou Baiyunshan Pharmaceutical Holdings Company Earnings release: Q1 2026 - Filings
- 2 months ago - Guangzhou Baiyunshan Pharmaceutical Holdings Company Earnings release: Q4 2025 - Filings
- 2 months ago - Guangzhou Baiyunshan Pharmaceutical Holdings Company Annual report: Q4 2025 - Filings
- 7 months ago - Guangzhou Baiyunshan Pharmaceutical Holdings Company Earnings release: Q3 2025 - Filings
- 10 months ago - Guangzhou Baiyunshan Pharmaceutical Holdings Company Quarterly report: Q2 2025 - Filings
- 10 months ago - Guangzhou Baiyunshan Pharmaceutical Holdings Company Earnings release: Q2 2025 - Filings